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ABSTRACT
Background: Progestogen‑only injectable contraceptives (POICs) remain the most popular contraceptive method in Nigeria. 
Considering how widely used POICs are worldwide, there is little published evidence of their safety and effectiveness. There 
is also a paucity of research to determine associations between the influence of age and parity and the preferred choice of 
POICs in women.
Aim: This study was to determine the use prevalence and the influence of age and parity on the preferred choice of POIC, 
and also the reasons for discontinuation among users of POICs at the family planning clinics of OAUTHC, Ile‑Ife.
Materials and Methods: A retrospective record of 324 women who chose POICs out of a total of 1,029 clients seen at the 
family planning units of the hospital was collected for the period between January and December 2015. Information relevant 
to this study objectives was extracted using a purpose‑designed proforma. Data were analyzed with SPSS version 16, and 
results were presented as frequencies and percentages. Pearson Chi‑square test was used as test of significance where 
applicable and a P value < 0.05 was considered statistically significant.
Results: The prevalence of POIC during the study period was 31.49%. Depo‑Provera (depot medroxyprogesterone 
acetate [DMPA]) was the most popular injectable preferred by the women. Age and parity had significant effects on the 
preferred injectable contraception with P values of 0.032 (CI 0.088‑0.099) and 0.002 (CI 0.009‑0.013), respectively, as younger 
clients with lower parity preferred Noristerat while preference for DMPA increased with age and parity. Majority (67%) did 
not experience any side effect; secondary amenorrhea was the most common side effect experienced by 27% of the clients. 
Only 34% continued with the method for the duration of study while 66% discontinued for different reasons.
Conclusion: POICs are very effective and safe long‑acting reversible method of contraception. While DMPA may be the 
more popular overall choice, norethisterone enanthate (NET‑EN) is preferable in younger women of low parity.
Key words: Depoprovera; Ile‑Ife; Noristerat.
Introduction
Decision making concerning fertility control is, for many 
people, a deeply personal and sensitive issue, often involving 
religious or philosophical convictions.[1] Family planning 
refers to a conscious effort by a couple to limit or space 
the number of children they want to have through the use 
of contraceptive methods.[2] Nigeria constitutes 2% of the 
world population but accounts for 10% of global maternal 
A review of clinical experience with progesterone‑only 
injectable contraceptives at OAUTHC, Ile‑Ife
Adebimpe O Ijarotimi1, Boluwatife S Idowu1,2, Oluwaseun O Sowemimo1, Adebanjo B Adeyemi1,  
Ernest O Orji1
1Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo University/Teaching Hospitals Complex, Ile‑Ife,  
Osun State, 2Nigeria Airforce, Mother and Child Hospital, Badagry, Lagos, Nigeria







How to cite this article: Ijarotimi AO, Idowu BS, Sowemimo OO, 
Adeyemi AB, Orji EO. A review of clinical experience with progesterone‑
only injectable contraceptives at OAUTHC, Ile‑Ife. Trop J Obstet Gynaecol 
2018;35:170‑6.
This is an open access journal, and articles are distributed under the terms of the Creative 
Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to 
remix, tweak, and build upon the work non-commercially, as long as appropriate credit 
is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com
Ijarotimi, et al.: POICs at Ile-Ife
171Tropical Journal of Obstetrics and Gynaecology / Volume 35 / Issue 2 / May‑August 2018
deaths, about 60,000 maternal deaths occur annually in 
Nigeria.[3] Knowledge of contraception is widespread in 
Nigeria; 85% of women and 95% of men report knowing about 
a contraceptive method,[2] but the contraceptive prevalence 
rate is low. Fifteen percent of currently married women use 
a contraceptive method, an increase of only 2 percentage 
points from the 2003 Nigeria Demographic and Health 
Survey (NDHS). Ten percent of currently married women 
report using a modern method. Injectables remain the most 
popular contraceptive method among them.[2]
The high level of awareness about contraception but very low 
level of use has been established in studies in Nigeria.[4-7] The 
2013 NDHS results indicate that the total fertility rate (TFR) 
is 5.5 births per woman. Overall, Nigerian women have 
about one child more than the number they want. This high 
fertility rate accounts for Nigeria’s high maternal, infant, and 
neonatal mortalities.[8]
Steroid sex hormones may be injected intramuscularly to 
provide a depot, which, depending on the drug, dosage, 
and formulation, may provide contraception for 1 month, 
6 months, or even 1 year. A pure progestin may be used, or 
the injection may consist of a combination of a progestin 
with an estrogen. Most of these regimens prevent ovulation 
by suppression of anterior pituitary function.[1] There are two 
commonly used injectable progestogen-only contraceptives 
that have been available in many countries in the world 
since 1983.[9] These are depot medroxyprogesterone 
acetate (DMPA) and norethisterone enanthate (NET-EN).
The  pharmacolog ica l  compos i t ion  o f  DMPA i s 
medroxyprogesterone acetate, a semi-synthetic derivative 
of progesterone that features the same pharmacological 
profile but is remarkably more potent. DMPA inhibits 
gonadotropin-releasing hormone pulsatility and gonadotropin 
secretion, and the luteinizing hormone (LH) is much more 
suppressed than the follicle-stimulating hormone (FSH), 
thereby effectively preventing ovulation. This results in the 
estradiol levels being low in long-term users.[10] NET-EN 
is administered at the dose of 200 mg every 60 days, and 
inhibits fertility through a mixed, two-phase mechanism: 
during the first portion of the drug’s half-life span, the 
contraceptive effect is exerted at the hypothalamic level, 
whereas later on when ovulation is restored, the action 
is likely to be peripheral on the cervical mucus and/or the 
endometrium.[9,11]
Ideally, both progestogen-only injectable contraceptives 
(POICs) should be started within 5 days of the menstrual 
cycle, to rule out pregnancy. Injection in the first 7 days of 
menses results in immediate ovulation suppression. However, 
POICs can be commenced at any stage of the menstrual 
cycle, providing that the woman is not pregnant. The quick 
start method means that she does not have to wait for her 
next menses to begin. The 14-day rule should be observed, 
which means that she must abstain from, or have protected 
sexual intercourse, for 14 days after the administration of 
the injection if started in mid-cycle.[12]
Progestogen-only injectables are very effective methods of 
fertility control with published failure rates of 0.3% in the first 
year of use.[13] After the injections are discontinued, there may 
be considerable delay in reestablishment of regular ovulation 
and corresponding true menstrual bleeding. However, 
fertility rates are essentially normal at about 18 months after 
discontinuation.[1]
An advantage of the drug is that its use is independent of 
coitus or a daily activity such as pill taken.[1] Therefore being 
discreet, it enables the women to maintain secrecy about 
their use of contraception,[14] especially in some African 
settings where the use of contraception is discouraged 
due to cultural or religious reasons. POICs also offer the 
advantage of not requiring special storage (making them 
suitable for use in tropical countries like Nigeria).[14] Lactating 
mothers can successfully breast feed their babies as the 
POICs do not adversely affect milk composition, quality, or 
quantity.[15] Reported noncontraceptive benefits of POICs 
include reduction in frequency of sickle cell crises, reduction 
of menstrual cycle disorders, less dysmenorrhoea, less 
symptoms of premenstrual tension, and reduction in seizure 
frequency in women with epilepsy.[16]
Bone mineral density may be reduced among those who 
receive injections of medroxyprogesterone. Changes in 
bone density appear similar to those seen during lactation. 
Subgroups of long-term users of Depo-Provera may 
experience a decrease in spinal bone density that appears 
to be reversible following discontinuation.[1] Changes in the 
menstrual cycle are inevitable with injectable contraceptives, 
and are commonly referred to as “menstrual chaos.” Changes 
in menstrual patterns may result in amenorrhea and 
breakthrough bleeding.
Withdrawal bleeding may be heavy, irregular, or absent, and 
there may be spotting. Amenorrhea is a predictable side 
effect of DMPA and NET-EN owing to the inhibition of both 
ovulation and follicular development.[10] Amenorrhea may 
be generally more acceptable to women than prolonged 
or frequent bleeding.[17] Side effects other than irregular 
bleeding that may be encountered include a delay in ovulation 
when discontinued; thus when a delay in return to fertility, 
mildly androgenic effects may increase existing depression, 
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acne, and hair loss.[10] Others are weight gain, headache, 
nervousness, abdominal discomfort, dizziness, and fatigue.[1]
Justification
Nigeria has one of the highest maternal mortality ratios in 
sub-Saharan Africa, and ranks as the country with the second 
highest number of maternal deaths in the world.[18] Use of 
long-acting reversible methods is proposed as a strategy 
to reverse undesirable maternal health consequences in 
developing countries.[19,20]
Considering how widely used DMPA is worldwide, there is 
little published evidence of its safety and effectiveness.[21] 
There is also paucity of research to determine associations 
between the influence of age and parity and the preferred 
choice of POICs in women.
Aim
This study aims to determine the use prevalence, the 
influence of age and parity on the preferred choice of POIC, 
side effects, and discontinuation rate as well as the reasons 
for discontinuation among users of POICs at the family 
planning clinics of our hospitals.
Materials and Methods
Study location
This study reviewed the clinical experience with POICs chosen 
by women accessing family planning services in a Nigerian 
teaching hospital family planning unit. The health facility 
consists of two hospitals and two primary health care centers. 
These hospital units serve not only the health administrative 
zone in which they are located but also receive clients from 
other parts of Osun State and some parts of Oyo, Ondo, and 




A retrospective record of 324 women who chose POICs at the 
family planning units of the hospital out of a total of 1,029 
clients seen was collected for the period between January 
and December 2015. After due counseling by family planning 
nurses and physicians, a full medical history was taken and 
clinical examination as well as pregnancy test were performed 
to exclude known contraindications to POIC and pregnancy.
DMPA marketed as Depo-Provera® and NET-EN marketed as 
Noristerat® are the two POICs available in Nigeria. A dose 
of 200 mg NET-EN or 150 mg DMPA was injected into the 
gluteal/deltoid muscle within the first 7 days of a normal 
menstrual period where menstrual dates were known. It 
was also given after abortion and 6 weeks after delivery in 
breastfeeding mothers who were yet to resume menstruation. 
Repeat injections and observations were done after every 
60 days for those receiving NET-EN and every 90 days for 
clients on DMPA. At each visit, all the complaints volunteered 
by the patient were documented. The weight, blood 
pressure, and result of urinalysis were recorded. A patient 
was considered lost to follow up if she defaulted more than 
twice from scheduled injections.
A total of 324 clients had POICs within the period under study 
out of which 18 had incomplete records and were therefore 
excluded from the study leaving a total of 306 files which were 
complete. Information about age, marital status, highest level 
of education, parity, previously used contraceptive methods, 
preferred injectable contraception, side effects experienced 
by the POIC acceptors, discontinuation, and reasons for 
discontinuation were extracted from the hospital records 
using a purpose-designed proforma.
Data analysis
Analysis was done with respect to use prevalence, profile 
of the acceptors, and discontinuation rate over the period 
of study. The influence of age and parity was considered 
on the choice of preferred injectable contraceptive. Data 
were cleaned and analyzed with Statistic Package for Social 
Sciences version 16; results were presented as frequencies 
and percentages. Pearson Chi-square test was used as test 
of significance where applicable and a P value < 0.05 was 
considered statistically significant.
Limitations of the study
The retrospective nature of this study prevented direct 
access to the clients and thereby increased the incidence 
of incomplete records. Also being a hospital-based study, it 
cannot give a true picture of the use prevalence of POICs for 
this environment because of other sources of obtaining the 
injectable contraceptive such as primary health care centers 
and patent medicine vendors. This review, however, was able 
to address the study objectives and provided information 
that can be used for further studies, training of contraceptive 
providers, program planning, and policy formulation.
Results
A total of 1,029 clients were seen at the two family planning 
units of the hospital between January to December 2015; 
324 of these clients accepted POICs after due counseling. 
The use prevalence of POICs during the study period was 
31.49%. Eighteen of the clients had incomplete records and 
were therefore excluded from the study leaving a total of 
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306 files which are complete. The POICs acceptors were 
between the ages of 20 and 45 years with mean ± standard 
deviation (SD) of 32.68 ± 4.76 years as shown in Figure 1.
Table 1 revealed that majority (60%) of the acceptors 
were educated up to secondary school level. Parity of the 
acceptors in Table 2 ranged from 1 to 7 with a mean ± SD 
of 3.37 ± 1.34. Table 3 showed that fresh acceptors 
accounted for 35% of the POICs clients, about 25% of the 
acceptors migrated from natural family planning to modern 
contraception, while the remaining 40% switched from 
other modern methods. Depo-Provera (DMPA) was the 
most popular injectable preferred by 63% of the women 
while 37% opted for Noristerat (NET-EN) as depicted in 
Figure 2.
Age and parity had significant effects on the preferred injectable 
contraception with P values of 0.032 (CI 0.088-0.099) and 
0.002 (CI 0.009-0.013), respectively, as younger clients with 
lower parity preferred Noristerat (NET-EN) while preference 
for Depo-Provera (DMPA) increased with age and parity as 
shown in Tables 4 and 5. Table 6 revealed that majority (67%) 
did not experience any side effect; 27% experienced 
secondary amenorrhea which was the commonest side effect. 
The discontinuation rate in Figure 3 revealed that only 34% 
continued with the method for the duration of study while 
66% discontinued for different reasons. Table 7 showed that 
the reasons given for discontinuation were mainly menstrual 
abnormalities in 49% of the women and inability to keep 
up with the appointments in 43%. There was no accidental 
pregnancy recorded during the study period.
Table 3: Previously used contraception by POICs acceptors
Methods Frequency Percentage
None 108 PREVIOUS 35.3
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Discussion
The use prevalence of POICs during the study period was 
31.49%. This is higher than the incidence of 12.6%, 22.1%, and 
23.3% obtained from earlier studies at Ile-Ife,[22] Oshogbo,[23] 
and Calabar[15] in Southwest and South South Nigeria, 
respectively. This rise may be attributable to the slight 
increase in the national contraceptive prevalence rate 
from 13% to 15% and increasing acceptability of injectable 
contraceptives having become the most popular contraceptive 
method.[2] Religious and sociocultural influences on the 
choice of contraception can explain the higher values of 
64.6% and 50.7% obtained from Kano[24] and Zaria[25] both in 
Northwest Nigeria.
The POI injectable acceptors were between the ages of 20 
and 45 years with mean ± SD of 32.68 ± 4.76 years. This 
is comparable with the age profile in similar studies by 
Adeyemi et al.[23] and Njoku et al.[15] About 63% of them were 
in the age group of 20 to 34 years; clients older than 35 years 
accounted for less than 37% of the study population. This 
was not unexpected because ages 20 to 35 years represent 
the peak reproductive period with high fecundability, then 
declining fertility in later years.
Contraceptive use is positively associated with women’s 
level of education and contraceptive use increases with 
educational attainment.[2] Majority (60%) of the acceptors in 
this study were educated up to secondary school level while 
less than 4% had no education at all. This is in keeping with 
findings from the national surveys that 37% of women who 
have more than a secondary education use a contraceptive 
method, as compared with only 3% of women with no 
education.[2]
Parity of the acceptors in this study ranged from 1 to 7 with 
more than half (52%) between Para 1 and 3 while parity greater 
than 6 constituted only 4%. This may be due to the fact that 
clients with higher number of children were likely to be older 
and likely to have completed their family size, and may find 
longer acting contraceptives like Intrauterine Contraceptive 
Device (IUCD) and implants more suitable than injectables.
Fresh acceptors constituted 35% of the POI clients in this 
study while 43% switched from other modern methods such as 
condoms, pills, IUCD, emergency contraception, and implants 
to POI method. These values were slightly lower than 41.3% 
and 58.7% obtained for fresh acceptors and previous use 
of modern contraceptives obtained from a similar study.[23] 
The difference may be due to variations in contraceptive 
counseling skills and individual client’s perception of the 
different contraceptive methods.
The finding that 25% of the acceptors migrated from natural 
family planning methods like withdrawal and periodic 
abstinence to an effective modern method of contraception 
like POI is not surprising considering the high failure rates 
associated with such natural methods of family planning. 
In this study, the popularity of Depo-Provera (DMPA) 
which was preferred by 63% of the women versus 37% for 
Noristerat (NET-EN) is in keeping with findings from several 
studies on POI.[15,23,26] This popularity may be due to the 
reduced frequency of clinical visits associated with DMPA 
compared with NET-EN.
The influence of age and parity on the preferred choice 
of POI is a unique aspect of this study which was not 
considered in previous studies on POI that were reviewed. 
Age and parity had significant effects on the preferred 
Table 4: Influence of age on the preferred injectable
Age groups DMPA NET‑EN Total
20‑24 3 9 12
25‑29 27 39 66
30‑34 67 53 120
35‑39 64 18 82
40‑44 20 5 25
45‑50 0 1 1
Total 181 125
P (95% CI) 0.032 (0.088‑0.099)
Table 5: Influence of parity of the preferred injectable
Parity groups DMPA NET‑EN Total
1‑3 73 85 158
4‑6 98 38 136
7‑9 10 2 12
Total 181 125 306
P (95% CI) 0.002 (0.009‑0.013)
Table 7: Reasons for discontinuation of POICs
Reasons Frequency Percentage
Ready for another baby 10 3.27
Menstrual abnormalities 149 48.69
Inability to keep appointments 133 43.46
No reason 14 4.58
Total 306 100
Table 6: Side‑effects experienced by POICs acceptors




Breakthrough bleeding 1 0.3
Weight gain 16 5.2
Abnormal vaginal discharge 1 0.3
Total 306 100
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injectable contraception as younger clients with lower 
parity preferred Noristerat (NET-EN) while preference for 
Depo-Provera (DMPA) increased with age and parity. This 
perhaps may be due to the fact that Noristerat (NET-EN) 
is suited to women who prefer the reduced likelihood of 
amenorrhea and require a shorter return time to fertility.[10] 
This reflects the needs of younger women with lower parity.
The finding that majority (67%) of the clients in this study did 
not experience any side effect is a welcome development which 
will encourage such users. Secondary amenorrhea is the most 
common side effect experienced by 27% of the acceptors which 
is consistent with findings from several similar studies.[15,23-27] 
The discontinuation rate from this study was 66%. Only 34% 
continued with the method for the duration of study while 66% 
discontinued for different reasons which is unacceptably high. 
Although this discontinuation rate is slightly lower than the 
finding from a similar study in Port-Harcourt which reported 
a 77% cumulative discontinuation rate,[26] it is, however, much 
higher than 19% and 22% reported in studies from Calabar 
and Osogbo, respectively.[15,23] Four noncomparative studies 
from the United States demonstrated discontinuation rates 
among DMPA users ranging from 41% to 77% at 1 year. Another 
study also showed cumulative discontinuation rates up to 79% 
among DMPA users at 5 years.[28-31]
Reasons given for discontinuation were mainly menstrual 
abnormalities in 49% of the women and inability to keep 
up with the appointments in 43%. Regular menstruation is 
perceived as a sign of healthy reproductive function and 
general well-being. There are myths about the absence of 
menstruation leading to a buildup of bad blood in the body 
and making the woman ill. Also breakthrough/unpredictable 
bleeding can be inconvenient as well as a source of 
embarrassment. Therefore, irregular menses is a major cause 
of apprehension and anxiety in these women with little 
tolerance for the cause. These factors may be responsible 
for the high discontinuation rate which is in keeping with 
the reasons cited from several studies.[10,15,23,26]
Appropriate counseling to disabuse the myths, repeated 
reassurance, and short-term use of combined oral pills to 
correct the abnormal bleeding patterns may help to reduce 
the rate of discontinuation in those experiencing these 
side effects. There was no accidental pregnancy recorded 
in the clients during the study period which confirmed the 
effectiveness of POI as evidenced by other similar studies.[13,23]
Conclusions and Recommendations
POICs are very effective and safe long-acting reversible 
contraceptives. While DMPA may be the more popular overall 
choice, NET-EN is preferable in younger women of lower 
parity. Majority of the women studied tolerated POICs well 
but the rate of discontinuation was rather high. Adequate 
counseling and information to prepare the minds of the 
clients about the menstrual disruption, constant reassurance, 
support, and measures to correct abnormal bleeding can help 
to reduce the discontinuation rate.
Information technology also has a role to play in the form of 
programmed short message service (sms) reminders that can 
be sent to the clients around the due date of their injections. 
This will help to reduce the incidence of clients failing to 
turn up for their appointments and enhance continuation.
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